NCT03401385 - First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01) | Biotech Hunter

Enrollment

890

Participants

Timeline

Start Date

January 31, 2018

Primary Completion Date

January 1, 2027

Study Completion Date

January 1, 2027

Conditions

Hormone Receptor Positive Breast CancerTriple Negative Breast CancerNon-small Cell Lung Cancer

Interventions

DRUG

Datopotamab Deruxtecan (Dato-DXd)

A total anti-TROP2 antibody and MAAA-1181a

DRUG

Steroid Containing Mouthwash

A mouthwash containing a steroid ingredient administered in sub-study

OTHER

Non-Steroid Containing Mouthwash

A mouthwash containing a non-steroid ingredient administered in sub-study

Trial Locations (18)

10029

Tisch Cancer Institute, Icahn School of Medicine, New York

10065

Memorial Sloan-Kettering Cancer Center, New York

20016

Johns Hopkins Sibley Memorial Hospital, Washington D.C.

21287

Johns Hopkins University, Baltimore

22031

Virginia Cancer Specialists, Fairfax

30322

Winship Cancer Institute of Emory University, Atlanta

37205

Sarah Cannon Research Institute, Nashville

77030

MD Anderson Cancer Center, Houston

78229

Next Oncology, San Antonio

START Oncology, San Antonio

90095

University of California, Los Angeles, Los Angeles

02114

Massachusetts General Hospital, Boston

02115

Dana-Farber Cancer Institute, Boston

464-8681

Aichi Cancer Center, Nagoya

135-8550

The Cancer Institute Hospital of Japanese Foundation For Cancer Research, Koto-Ku

142-0064

Showa Medical University Hospital, Shinagawa-Ku

104-0045

National Cancer Center Hospital, Chūōku

277-8577

National Cancer Center Hospital East, Kashiwa